Jan Borén, MD, PhD

Jan Borén is chair of the Department of Molecular and Clinical Medicine, Institute of Medicine at the Sahlgrenska Academy; director of the strategic research center Sahlgrenska Center for Cardiovascular and Metabolic Research (CMR), and consultant physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital.

Professor Borén’s longterm interests are to define the mechanisms that regulate secretion and metabolism of atherogenic lipoproteins and clarify their atherogenicity; to develop strategies to prevent retention of atherogenic lipoproteins and identity novel biomarkers for cardiovascular disease; and to elucidate how cardiac uptake of lipoproteins induces lipotoxicity and insulin resistance. His research program is translational and involves both in vitro and in vivo studies, including pathophysiological studies based on vascular and myocardial cells, biopsies and mouse models, and kinetic studies in carefully phenotyped human volunteers.

TITLE OF HIS SPEECH : Fatty liver, lipoprotein metabolism and cardiovascular risk

Maria Luz Martínez Chantar, PhD

Hepatic cirrhosis is a worldwide global health problem currently without successful pharmacological therapeutic approaches that can halt progression to decompensated cirrhosis or even reverse cirrhosis. Importantly, neddylation is a post-translational modification relevant in cell cycle regulation and inflammation recently identified to be altered in the progression of cirrhosis to hepatocellular carcinoma.

Neddylation activity has been evaluated both in clinical cirrhosis and in a cirrhotic mouse model of bile-duct ligation and CCL4. Cirrhotic mice were treated with MLN4924, a small molecule neddylation inhibitor, and cirrhosis hallmarks assessed. Furthermore the effects of neddylation pharmacological inhibition in vitro on bile acid-induced hepatocyte injury, lipopolysaccharide-induced Kupffer cell activation and in activated hepatic stellate cells, was evaluated.

We have showed for the first time a deregulation of the neddylation activity both in clinical and in an in vivo experimental model of liver cirrhosis. Furthermore, neddylation pharmacological inhibition in vivo increases mice survival by improving hepatic fibrosis and reversal of the cirrhotic phenotype by a multifactorial process affecting different liver cell types. On one hand, neddylation inhibition in vitro results in reduced hepatocyte death and inflammation related to decreased Kupffer cell activation in a process mediated by reduced NFkB activation, and on the other hand is able to induce hepatic stellate cell apoptosis and reduced activation either by promoting mitochondrial dysfunction or as result of the TGFb downstream target, c-Jun, accumulation.

Overall, targeting of the neddylation pathway is suggested as a potential and attractive novel therapeutic approach in liver cirrhosis.

Jimmy Bell, PhD

Professor Jimmy D Bell completed his PhD in Biochemistry in 1987 (London). He has worked extensively on the development and application of in vivo techniques for the study of disease development, with especial focus on adipose tissue and liver metabolism. Jimmy joined the MRC Clinical Sciences Centre (Imperial College London) in the mid1990s, where he was appointed Group Head. He recently moved to the University of Westminster to establish a new Research Centre for Optimal Health (ReCOH).
Jimmy has published over 200 peerreviewed papers and authored over a dozen chapters for scientific books.

TITLE OF HIS SPEECH : Hepatic Steatosis

Charlotte Ling, PhD

Dr Ling obtained her PhD in Endocrinology at University of Gothenburg, Sweden in 2002. After a postdoc at Lund University, where she studied genetics of type 2 diabetes, she dedicated her research to the study of epigenetic mechanisms contributing to type 2 diabetes.
Her research group has been involved in many epigenetic discoveries in type 2 diabetes. The group has identified epigenetic modifications in patients with type 2 diabetes and they have shown that genetic and environmental risk factors alter the epigenetic pattern in human pancreatic islets, skeletal muscle and adipose tissue. Charlotte Ling’s research is well funded by both national and international funds e.g. she has been awarded a 5 year excellence grant from the Novo Nordisk foundation, EFSD grants and research career grants from the Swedish Research council.

TITLE OF HER SPEECH : Alterations in DNA methylation and type 2 diabetes

Pierre Bedossa, PhD

Pierre Bedossa is professor of pathology at the University of Paris. He is currently chairman of the Department of Pathology, Physiology, Nuclear Medicine and Imaging from The University Hospitals of Paris NordVal de Seine, France. His main topics of interest are dynamic of fibrosis, progression and regression, viral hepatitis and NASH. He is the founder of the METAVIR scoring system. He has published more than 350 original articles in peer reviewed journals.

TITLE OF HIS SPEECH : Histological classification of NAFLD: limits and perspectives

Sophie Lotersztajn , PhD

Dr. Sophie Lotersztajn serves as Research Director at the INSERM (INstitut de la Sant Et de la Recherche M dicale) in France. Dr. Lotersztajn serves as Principal Investigator and Head of the group Molecular mechanisms of liver fibrosis at the Hospital Henry Mondor in Creteil, Paris. She serves as Member of Scientific Advisory Board at BiOrion Technologies BV. She is author of many publications in highranking journals, all about the molecular regulation of hepatic fibrosis. Dr. Lotersztajn is member of the Scientific Committee of INSERM, member of the Editorial Board of American Journal of Physiology and member of the Editorial Board of  Molecular Pharmacology.

TITLE OF HER SPEECH : Immunoregulation of liver fibrosis: novel targets